Correction: Masitinib for mild-to-moderate Alzheimer’s disease: results from a randomized, placebo-controlled, phase 3, clinical trial
Main Authors: | Bruno Dubois, Jesús López‑Arrieta, Stanley Lipschitz, Triantafyllos Doskas, Luiza Spiru, Svitlana Moroz, Olena Venger, Patrick Vermersch, Alain Moussy, Colin D. Mansfield, Olivier Hermine, Magda Tsolaki, for the AB09004 Study Group Investigators |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2023-04-01
|
Series: | Alzheimer’s Research & Therapy |
Online Access: | https://doi.org/10.1186/s13195-023-01230-9 |
Similar Items
-
Masitinib for mild-to-moderate Alzheimer’s disease: results from a randomized, placebo-controlled, phase 3, clinical trial
by: Bruno Dubois, et al.
Published: (2023-02-01) -
Efficacy and Safety of Masitinib in Corticosteroid-Dependent Severe Asthma: A Randomized Placebo-Controlled Trial
by: Davidescu L, et al.
Published: (2022-06-01) -
Interaction of Masitinib with Organic Cation Transporters
by: Saliha Harrach, et al.
Published: (2022-11-01) -
Masitinib Inhibits Hepatitis A Virus Replication
by: Reina Sasaki-Tanaka, et al.
Published: (2023-06-01) -
MasitinibL shows promise as a drug-like analog of masitinib that elicits comparable SARS-Cov-2 3CLpro inhibition with low kinase preference
by: Olanrewaju Ayodeji Durojaye, et al.
Published: (2023-04-01)